Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.68 USD
−109.06 M USD
0.00 USD
17.01 M
About Pharvaris N.V.
Sector
CEO
Berndt A. E. Modig
Headquarters
Leiden
Website
Founded
2015
ISIN
NL00150005Y4
FIGI
BBG00YYCW1N8
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PHVS is 22.29 USD — it has increased by 5.94% in the past 24 hours. Watch Pharvaris N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pharvaris N.V. stocks are traded under the ticker PHVS.
PHVS stock has risen by 8.47% compared to the previous week, the month change is a 0.45% rise, over the last year Pharvaris N.V. has showed a 39.05% increase.
We've gathered analysts' opinions on Pharvaris N.V. future price: according to them, PHVS price has a max estimate of 47.09 USD and a min estimate of 13.87 USD. Watch PHVS chart and read a more detailed Pharvaris N.V. stock forecast: see what analysts think of Pharvaris N.V. and suggest that you do with its stocks.
PHVS reached its all-time high on Feb 22, 2021 with the price of 42.86 USD, and its all-time low was 1.77 USD and was reached on Dec 2, 2022. View more price dynamics on PHVS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PHVS stock is 8.49% volatile and has beta coefficient of 1.45. Track Pharvaris N.V. stock price on the chart and check out the list of the most volatile stocks — is Pharvaris N.V. there?
Today Pharvaris N.V. has the market capitalization of 1.20 B, it has increased by 3.39% over the last week.
Yes, you can track Pharvaris N.V. financials in yearly and quarterly reports right on TradingView.
Pharvaris N.V. is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
PHVS earnings for the last quarter are −0.86 USD per share, whereas the estimation was −0.66 USD resulting in a −30.06% surprise. The estimated earnings for the next quarter are −0.74 USD per share. See more details about Pharvaris N.V. earnings.
Pharvaris N.V. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
PHVS net income for the last quarter is −45.82 M USD, while the quarter before that showed −32.01 M USD of net income which accounts for −43.16% change. Track more Pharvaris N.V. financial stats to get the full picture.
No, PHVS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 82.00 employees. See our rating of the largest employees — is Pharvaris N.V. on this list?
Like other stocks, PHVS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pharvaris N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pharvaris N.V. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pharvaris N.V. stock shows the strong buy signal. See more of Pharvaris N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.